N-([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-2-amine

We are N-([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-2-amine CAS:1372775-52-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:N-([1,1'-biphenyl]-4-yl)-[1,1'-biphenyl]-2-amine
CAS.NO:1372775-52-4
Synonyms:biphenyl-2-yl-biphenyl-4-yl-amine
BIPHENYL-4-YL-BIPHENYL-2-YL-AMINE
biphenyl-2-ylbiphenyl-4-ylamine
Molecular Formula:C24H19N
Molecular Weight:321.41400
 
Physical and Chemical Properties:
Melting point:35ºC
Boiling point:112ºC
Flash point:87ºC
 
Specification:
Appearance:White crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates

N-([1,1'-biphenyl]-4-yl)-[1,1'-biphenyl]-2-amine


Related News: At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.3-methylthiopropanal CAS:3268-49-3 From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity.3886-70-2 As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.1-Methyl-4-piperidone Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.

Related Products
Product Name
2,5-Diamino-4,6-dihydroxypyrimidine hydrochloride View Details
2,3-Difluorophenol View Details
1,2-dibromobenzene View Details
1-Butaneboronic acid manufacturer Perchloromethylmercaptan manufacturer 3-Chloro-6-(trifluoromethyl)pyridazine manufacturer 2-FLUORO-6-METHOXYBENZOIC ACID manufacturer (2R,3R)-Diisopropyl 2,3-dihydroxysuccinate manufacturer